Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
bispecific antibodies
Biotech
Merck pays $588M for bispecific to defend Keytruda’s kingdom
The outlay, plus up to $2.7 billion in milestones, has secured Merck global rights to LaNova Medicines’ PD-1xVEGF bispecific antibody.
Nick Paul Taylor
Nov 14, 2024 7:45am
Celldex drops phase 1 tumor bispecific to focus on inflammation
Nov 7, 2024 7:25am
Genmab axes 3 programs to focus on plumped-up pivotal pipeline
Nov 7, 2024 5:41am
FDA delays decision on Merus' first-in-class cancer drug
Nov 5, 2024 9:14am
Roche MAGE-A4 trial withdrawn after strategic review
Oct 18, 2024 5:30am
Context builds bispecific bank with $133M biobucks deal
Sep 23, 2024 11:20am
